- Home
- MYGN vs MYRG Comparison
MYGN vs MYRG Comparison
Compare MYGN & MYRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- MYRG
- Stock Information
- Founded
- MYGN 1991
- MYRG 1891
- Country
- MYGN United States
- MYRG United States
- Employees
- MYGN N/A
- MYRG N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- MYRG Water Sewer Pipeline Comm & Power Line Construction
- Sector
- MYGN Health Care
- MYRG Industrials
- Exchange
- MYGN Nasdaq
- MYRG Nasdaq
- Market Cap
- MYGN 2.0B
- MYRG 2.3B
- IPO Year
- MYGN 1995
- MYRG N/A
- Fundamental
- Price
- MYGN $12.39
- MYRG $147.72
- Analyst Decision
- MYGN Hold
- MYRG Strong Buy
- Analyst Count
- MYGN 12
- MYRG 5
- Target Price
- MYGN $23.92
- MYRG $162.40
- AVG Volume (30 Days)
- MYGN 1.0M
- MYRG 210.7K
- Earning Date
- MYGN 02-25-2025
- MYRG 02-26-2025
- Dividend Yield
- MYGN N/A
- MYRG N/A
- EPS Growth
- MYGN N/A
- MYRG N/A
- EPS
- MYGN N/A
- MYRG 2.29
- Revenue
- MYGN $823,600,000.00
- MYRG $3,536,692,000.00
- Revenue This Year
- MYGN $13.82
- MYRG N/A
- Revenue Next Year
- MYGN $4.59
- MYRG $2.93
- P/E Ratio
- MYGN N/A
- MYRG $64.45
- Revenue Growth
- MYGN 12.15
- MYRG 0.94
- 52 Week Low
- MYGN $12.17
- MYRG $86.60
- 52 Week High
- MYGN $29.30
- MYRG $181.02
- Technical
- Relative Strength Index (RSI)
- MYGN 29.80
- MYRG 47.93
- Support Level
- MYGN $12.17
- MYRG $138.29
- Resistance Level
- MYGN $15.08
- MYRG $149.60
- Average True Range (ATR)
- MYGN 0.79
- MYRG 4.90
- MACD
- MYGN -0.01
- MYRG -0.40
- Stochastic Oscillator
- MYGN 7.56
- MYRG 54.70
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
About MYRG MYR Group Inc.
MYR Group Inc is a U.S.-based holding company that provides specialty electrical construction services through its subsidiaries. The company operates through two segments. The transmission and distribution segment provides designing, engineering, procurement, construction, upgrade, maintenance, and repair services on transmission and distribution network and substation facilities. The commercial and industrial segment provides services such as the design, installation, maintenance, and repair of commercial and industrial wiring, installation of traffic networks, and the installation of bridges. MYR Group generates the majority of its sales from the United States and Canada.